phosphorylcholine has been researched along with Metastase in 12 studies
Phosphorylcholine: Calcium and magnesium salts used therapeutically in hepatobiliary dysfunction.
phosphocholine : The phosphate of choline; and the parent compound of the phosphocholine family.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In a multicenter, double-blind phase II trial, we compared the efficacy and safety of perifosine plus capecitabine (P-CAP) with placebo plus capecitabine (CAP) in patients with metastatic colorectal cancer (mCRC) who had progressed after as many as two prior therapies." | 9.15 | Randomized placebo-controlled phase II trial of perifosine plus capecitabine as second- or third-line therapy in patients with metastatic colorectal cancer. ( Bendell, JC; Campos, LT; Gardner, L; Hagenstad, C; Hermann, RC; Nemunaitis, J; Richards, DA; Sportelli, P; Vukelja, SJ, 2011) |
| "In a multicenter, double-blind phase II trial, we compared the efficacy and safety of perifosine plus capecitabine (P-CAP) with placebo plus capecitabine (CAP) in patients with metastatic colorectal cancer (mCRC) who had progressed after as many as two prior therapies." | 5.15 | Randomized placebo-controlled phase II trial of perifosine plus capecitabine as second- or third-line therapy in patients with metastatic colorectal cancer. ( Bendell, JC; Campos, LT; Gardner, L; Hagenstad, C; Hermann, RC; Nemunaitis, J; Richards, DA; Sportelli, P; Vukelja, SJ, 2011) |
| " Previously, we showed that dual liposomes simultaneously containing the hemostatic inhibitor, dipyridamole and the anticancer drug, perifosine potently inhibited metastasis, causing a 90% reduction in the number of lung metastases in a murine experimental metastasis model." | 3.76 | Inhibition of pulmonary metastasis in a human MT3 breast cancer xenograft model by dual liposomes preventing intravasal fibrin clot formation. ( Fichtner, I; Habedank, S; Haider, W; Wenzel, J; Zeisig, R, 2010) |
| "In this study, a panel of normal human prostate cells (HPCs) and tumor cells derived from metastases were studied by (1)H NMR spectroscopy to determine whether the malignant transformation of HPCs results in the elevation of choline compounds." | 3.71 | Detection of increased choline compounds with proton nuclear magnetic resonance spectroscopy subsequent to malignant transformation of human prostatic epithelial cells. ( Ackerstaff, E; Bhujwalla, ZM; Nelson, JB; Pflug, BR, 2001) |
| "Treatment with perifosine was complicated by fatigue and gastrointestinal toxicity." | 2.71 | A phase II study of perifosine in androgen independent prostate cancer. ( Arlen, PM; Chen, C; Chung, EJ; Dahut, WL; Daniels, A; Figg, WD; Gulley, J; Jones, E; Lee, MJ; Parnes, HL; Posadas, EM; Sparreboom, A; Steinberg, SM; Trepel, JB; Trout, A; Wright, J, 2005) |
| "Formation of lung and extrapulmonary metastases after intravenous administration of MT3 breast cancer cells was significantly reduced when mice were treated with a single intravenous dose of DIP/OPP-L containing 100nmol lipid 6h before tumour cell inoculation." | 1.35 | Inhibition of breast cancer metastasis by dual liposomes to disturb complex formation. ( Fichtner, I; Wenzel, J; Zeisig, R, 2009) |
| "In human MDA-MB-231 breast cancer cells, the maximum inhibition of protein expression ranged from 84% (OPN) to 75% (BSPII) and 70% (ON)." | 1.32 | Downregulation of osteopontin and bone sialoprotein II is related to reduced colony formation and metastasis formation of MDA-MB-231 human breast cancer cells. ( Adwan, H; Bäuerle, TJ; Berger, MR, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (8.33) | 18.2507 |
| 2000's | 8 (66.67) | 29.6817 |
| 2010's | 3 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wenzel, J | 2 |
| Zeisig, R | 3 |
| Fichtner, I | 3 |
| Haider, W | 1 |
| Habedank, S | 1 |
| Amstalden van Hove, ER | 1 |
| Blackwell, TR | 1 |
| Klinkert, I | 1 |
| Eijkel, GB | 1 |
| Heeren, RM | 1 |
| Glunde, K | 1 |
| Bendell, JC | 1 |
| Nemunaitis, J | 1 |
| Vukelja, SJ | 1 |
| Hagenstad, C | 1 |
| Campos, LT | 1 |
| Hermann, RC | 1 |
| Sportelli, P | 1 |
| Gardner, L | 1 |
| Richards, DA | 1 |
| Beil, M | 1 |
| Micoulet, A | 1 |
| von Wichert, G | 1 |
| Paschke, S | 1 |
| Walther, P | 1 |
| Omary, MB | 1 |
| Van Veldhoven, PP | 1 |
| Gern, U | 1 |
| Wolff-Hieber, E | 1 |
| Eggermann, J | 1 |
| Waltenberger, J | 1 |
| Adler, G | 1 |
| Spatz, J | 1 |
| Seufferlein, T | 1 |
| Adwan, H | 1 |
| Bäuerle, TJ | 1 |
| Berger, MR | 1 |
| Whitehead, TL | 1 |
| Monzavi-Karbassi, B | 1 |
| Jousheghany, F | 1 |
| Artaud, C | 1 |
| Elbein, A | 1 |
| Kieber-Emmons, T | 1 |
| Posadas, EM | 1 |
| Gulley, J | 1 |
| Arlen, PM | 1 |
| Trout, A | 1 |
| Parnes, HL | 1 |
| Wright, J | 1 |
| Lee, MJ | 1 |
| Chung, EJ | 1 |
| Trepel, JB | 1 |
| Sparreboom, A | 1 |
| Chen, C | 1 |
| Jones, E | 1 |
| Steinberg, SM | 1 |
| Daniels, A | 1 |
| Figg, WD | 1 |
| Dahut, WL | 1 |
| Marsh, Rde W | 1 |
| Rocha Lima, CM | 1 |
| Levy, DE | 1 |
| Mitchell, EP | 1 |
| Rowland, KM | 1 |
| Benson, AB | 1 |
| Singer, S | 1 |
| Souza, K | 1 |
| Thilly, WG | 1 |
| Ackerstaff, E | 1 |
| Pflug, BR | 1 |
| Nelson, JB | 1 |
| Bhujwalla, ZM | 1 |
| Stahn, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Placebo-Controlled Study of Perifosine in Combination With Single Agent Chemotherapy for Metastatic Cancer Patients[NCT00398879] | Phase 2 | 381 participants (Actual) | Interventional | 2005-08-31 | Completed | ||
| A Phase II Trial Of Oral Perifosine In Patients With Metastatic Androgen Independent Prostate Cancer[NCT00060437] | Phase 2 | 0 participants | Interventional | 2003-10-31 | Completed | ||
| Phase I Study of SNX-5422 Mesylate in Adults With Refractory Solid Tumor Malignancies and Lymphomas[NCT00644072] | Phase 1 | 33 participants (Actual) | Interventional | 2008-03-07 | Completed | ||
| Phase II Trial Of Perifosine In Locally Advanced, Unresectable Or Metastatic Pancreatic Adenocarcinoma[NCT00059982] | Phase 2 | 0 participants | Interventional | 2003-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 trials available for phosphorylcholine and Metastase
| Article | Year |
|---|---|
Randomized placebo-controlled phase II trial of perifosine plus capecitabine as second- or third-line therapy in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colore | 2011 |
A phase II study of perifosine in androgen independent prostate cancer.
Topics: Aged; Aged, 80 and over; Androgens; Antineoplastic Agents; Disease Progression; Drug Administration | 2005 |
A phase II study of perifosine in androgen independent prostate cancer.
Topics: Aged; Aged, 80 and over; Androgens; Antineoplastic Agents; Disease Progression; Drug Administration | 2005 |
A phase II study of perifosine in androgen independent prostate cancer.
Topics: Aged; Aged, 80 and over; Androgens; Antineoplastic Agents; Disease Progression; Drug Administration | 2005 |
A phase II study of perifosine in androgen independent prostate cancer.
Topics: Aged; Aged, 80 and over; Androgens; Antineoplastic Agents; Disease Progression; Drug Administration | 2005 |
A phase II trial of perifosine in locally advanced, unresectable, or metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Administration, Oral; Aged; Antiemetics; Child; Disease Progression; Drug Administra | 2007 |
9 other studies available for phosphorylcholine and Metastase
| Article | Year |
|---|---|
Inhibition of breast cancer metastasis by dual liposomes to disturb complex formation.
Topics: Animals; Antineoplastic Agents; Blood Platelets; Breast Neoplasms; Cell Line, Tumor; Dipyridamole; D | 2009 |
Inhibition of pulmonary metastasis in a human MT3 breast cancer xenograft model by dual liposomes preventing intravasal fibrin clot formation.
Topics: Animals; Antineoplastic Agents; Blood Coagulation; Blood Vessels; Cell Line, Tumor; Dipyridamole; Fe | 2010 |
Multimodal mass spectrometric imaging of small molecules reveals distinct spatio-molecular signatures in differentially metastatic breast tumor models.
Topics: Animals; Breast Neoplasms; Choline; Female; Glycerylphosphorylcholine; Humans; Magnetic Resonance Im | 2010 |
Sphingosylphosphorylcholine regulates keratin network architecture and visco-elastic properties of human cancer cells.
Topics: Actin Cytoskeleton; Carcinoma; Cell Movement; Cell Size; Cytoskeleton; Elasticity; Fluorescent Antib | 2003 |
Downregulation of osteopontin and bone sialoprotein II is related to reduced colony formation and metastasis formation of MDA-MB-231 human breast cancer cells.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Down-Regulation; Drug Therapy, Combination; Female; Gen | 2004 |
1H-NMR metabolic markers of malignancy correlate with spontaneous metastases in a murine mammary tumor model.
Topics: Animals; Antigens, Neoplasm; Biomarkers; Biomarkers, Tumor; Cell Adhesion; Cell Proliferation; Cell | 2005 |
Pyruvate utilization, phosphocholine and adenosine triphosphate (ATP) are markers of human breast tumor progression: a 31P- and 13C-nuclear magnetic resonance (NMR) spectroscopy study.
Topics: Adenosine Triphosphate; Biomarkers; Breast Neoplasms; Citric Acid Cycle; Female; Humans; Magnetic Re | 1995 |
Detection of increased choline compounds with proton nuclear magnetic resonance spectroscopy subsequent to malignant transformation of human prostatic epithelial cells.
Topics: Androgens; Cell Line; Cell Transformation, Neoplastic; Choline; Epithelial Cells; Humans; Male; Neop | 2001 |
Inhibition of carbohydrate mediated cell adhesion by liposomes as a possible [correction of possibile] way to prevent tumour metastasis.
Topics: Animals; Carbohydrate Metabolism; Carcinoma, Lewis Lung; Cell Adhesion; Cells, Cultured; CHO Cells; | 2002 |